DDD Partners LLC Sells 126,370 Shares of ARK Genomic Revolution ETF (BATS:ARKG)

DDD Partners LLC lowered its position in ARK Genomic Revolution ETF (BATS:ARKG) by 81.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 28,447 shares of the company’s stock after selling 126,370 shares during the period. DDD Partners LLC owned 0.05% of ARK Genomic Revolution ETF worth $670,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in ARKG. Hemington Wealth Management raised its holdings in ARK Genomic Revolution ETF by 44.6% in the fourth quarter. Hemington Wealth Management now owns 1,310 shares of the company’s stock worth $30,000 after purchasing an additional 404 shares in the last quarter. Union Bancaire Privee UBP SA purchased a new position in ARK Genomic Revolution ETF during the 4th quarter valued at about $45,000. National Bank of Canada FI boosted its stake in ARK Genomic Revolution ETF by 28.4% during the third quarter. National Bank of Canada FI now owns 4,155 shares of the company’s stock worth $106,000 after acquiring an additional 920 shares in the last quarter. IHT Wealth Management LLC purchased a new stake in ARK Genomic Revolution ETF in the third quarter worth about $203,000. Finally, Sanctuary Advisors LLC bought a new position in shares of ARK Genomic Revolution ETF during the second quarter valued at approximately $222,000.

ARK Genomic Revolution ETF Stock Up 24.6 %

ARKG stock opened at $29.42 on Monday. The firm’s 50-day simple moving average is $25.54 and its 200 day simple moving average is $25.24.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.